Reference materials used for specific safety evaluation of human immunoglobulin and human albumin products: features of development, certification and application

Human immunoglobulin and human albumin products can negatively affect patients’ health. The residual content of haemagglutinins, anti-D antibodies, prekallikrein activator, as well as the level of anticomplementary activity, are controlled during both production and testing for compliance with normative documentation. Methods for their quantitative evaluation are based on the effects of erythrocytes hemolysis or agglutination and on the amidolytic product properties of cascade reactions. These methods require the obligatory use of reference materials (RMs). The development of RMs, acting as the carrier of the quantitative characteristics of the human immunoglobulins and human albumin impurities, is fraught with the difficulty of selecting a candidate, substantiating the certification methodology, and determining the relevant characteristics. In this research, we used human immunoglobulin solutions with normalized haemagglutinin content, anti-D antibodies or anti-complementary activity in a different range, whose quality was studied using haemagglutination and chromogenic methods, and the complement fixation test. Methodological approaches to the RM development and certification were justified using system analysis and forensic audit methods. The results demonstrate the necessity of using RMs to assess the stability of analytical work by applying anti-complementary activity determination, haemagglutinin content or anti-Dantibody methods. It is established that RMs allow the quantitative content of haemagglutinins, anti-D antibodies and prekallikrein activator to be established. The value of the CRM characteristics should be approximated to the qualitative composition of these impurities in the analysed products, but in amounts not detectable (to produce negative RM components) or exceeding permissible maxima (to produce positive RM components).

1. Volkova R. A., Fadeikina O. V., Klimov V. I., Sakanyan E. I., Olefir Y. V., Merkulov V. A., Movsesyants A. A., Bondarev V. P., Borisevich I. V., Shvedov D. V. Topical issues related to reference standards in the sphere of circulation of biological products. BIOpreparations. Prevention, Diagnosis, Treatment. 2016;16(4):229–236. (In Russ.). Doi:10.30895/2221–996X-2016-16-4-229-236

2. GOST ISO Guide 34–2014 General requirements for the competence of reference material producers. Moscow, Standartinform Publ., 2016. (In Russ.)

3. Ph. Eur. Reference Standards. Available via https://www.edqm.eu/

4. European Pharmacopoeia EDQM. 9 Ed. Subscription required. Available via http://online6.edqm.eu/ep805/#.

5. National Institute for Biological Standards and Control. Biological reference materials // National Institute for Biological Standards and Control (NIBSC) [сайт]. URL: https://nibsc.org/ products.aspx

6. Food and Drug Administration [сайт]. URL: https://www.fda.gov/default.htm.

7. State Pharmacopoeia of the Russian Federation, XIII ed. Available via http://pharmacopoeia.ru/russian- pharmacopoeia/

8. Recommendations for the production and control of Haemophilus influenzae type b conjugate vaccines. WHO Technical Report Series. 2000;(897). Available via https://www. who.int/biologicals/publications/trs/areas/vaccines/influenza/ WHO_TRS_897_A1.pdf?ua=1

9. Borg A.-L. Investigation of method for determination of anticomplementary activity (ACA) in Octagam: master’s thesis. Stockholm. 2009. URL: http://liu.diva-portal.org/smash/get/ diva2:241409/fulltext01.pdf.

10. Krivykh MA, Kornilova OG, Kudasheva EY (2015) A method for obtaining a positive control of an RM of human immunoglobulin to determine the anti-complementary activity of human immunoglobulin preparations, and an RM of human immunoglobulin to determine the anti-complementary activity of human immunoglobulin preparation. RF Patent, 2577703 С1, 9 February 2015. (In Russ.)

11. Krivykh M. A. et al. Development of a reference standard for the determination of anticomplementary activity of human immunoglobulin. Pharmaceutical chemistry journal. 2015;49(6):40–42. (In Russ). Doi 10.30906/0023-1134-2015-49 -6-40-42

12. Krivykh M. A. et al. Certification of standard samples of human immunoglobulin For determination of anticomplementary activity. Pharmaceutical chemistry journal. 2016;50(12):61–64. (In Russ). Doi 10.30906/0023-1134-2016-50-12-61-64

13. Kornilova O. G., Krivykh M. A., Husnatdinova E. A., Konovalova E. S., Volkova R. A., Fadeykina O. V., Kudasheva E. Y., Movsesyants A. A. Contemplation of the possibility of extending the shelf life of human immunoglobulin reference standard used for determination of anticomplementary activity. BIOpreparations. Prevention, Diagnosis, Treatment. 2017;17(2):110–115. (In Russ.) Doi 10.30895/2221–996X-2017-17-2-110-115

14. Sandberg E., Daas A., Behr-Gross M-E. Collaborative Study to Establish Human Immunoglobulin BRP Batch 3 and Human Immunoglobulin (Molecular Size) BRP Batch 1. Pharmeuropa Bio. 2006;(1):37–49.

15. Russian Federation patent No. 2671415; (2017).

16. Kornilova O. G., Nechaev A. V., I. V. Borisevich, Kudasheva E. Y. Standardization of the method for determining hemagglutinin content in human immunoglobulin preparations in Russia. Pharmaceutical Chemistry Journal. 2017;51(11):57– 60. Doi 10.30906/0023-1134-2017-51-11-57-60

17. Pisani G., Wirz M., Gentili G. Anti-D testing in intravenous immunoglobulins: shouldn’t it be considered? // Vox. Sang. 1996;71(2):132. Doi 10.1046/j.1423–0410.1996.7120132.x

18. Turner C. E., Тhorpe S., Brasher M. Anti–Rh D Activity of Commercial Intravenous Immunoglobulin Preparations. // Vox. Sang. 1999;76(1):55–58. Doi 10.1046/j.1423–0410.1999.7610055.x

19. Kornilova O. G., Kudasheva E. Iu., Nechaev A. V., Struchkova I. N., Borisevich I. V. (2017) Reference material of anti-D antibody content in human immunoglobulin preparations. RF Patent application, № 2017144239, 2017 (In Russ.)

20. Krivykh M. A., Kornilova O. G., Zhuk I. E. Prekallikrein activator content in domestically-produced human albumin products. Medical Immunology. 2017;19(S. P.): 271–272.

21. Tomilin M. V., Filatova E. V., Kuznetsova M. M., Sudakova V. V., Zubkova N. V. Validation of the method for determination of prekallikrein activator in Human Albumin. BIOpreparations. Prevention, Diagnosis, Treatment. 2017;17(1):59–64. Doi 10.30895/2221–996X-2017-17-1-59-64